Subscribe To Our Free Newsletter |
Hot Stocks: Brokerages view on Indian Hotels, Titan Company, Paytm and Dr Lal PathLabs
Goldman Sachs maintained a sell rating on Dr Lal PathLabs with a target price of Rs 2200. The company reported a subdued volume growth and the trend continues.